Balcinrenone vs Finerenone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Mineralocorticoid receptor · full Heart Failure pipeline

Balcinrenone

Developed by AstraZeneca

Phase 3 in Heart Failuresmall molecule
Partial signal

NCT04595370 · Phase 2 · completed

The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.

Next expected readout: April 2027 · NCT06307652 (registry estimate)

No aligned efficacy figure on record for this race.

Finerenone · Kerendia

Marketed by Bayer

Approved in Heart Failuresmall molecule
Reliable signal

NCT04435626 · Phase 3 · completed

The trial randomized 6,016 participants to finerenone or matching placebo and masked participants, care providers, investigators, and outcome assessors. Its hard clinical primary endpoint was met: finerenone produced fewer cardiovascular death and recurrent heart-failure events than placebo, with a rate ratio of 0.84 (95% CI 0.74–0.95; p=0.0072).

Next expected readout: September 2027 · NCT07830940 (registry estimate)

Reported efficacy

Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months); Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events (met)

Result source: NCT04435626

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointBalcinrenoneFinerenone
CV death or HF hospitalisation—Trial running · NCT06307652—Trial running · NCT07270367
HF hospitalisation—Trial running · NCT06307652—Trial running · NCT07270367
CV death—Trial running · NCT06307652—Trial running · NCT07270367
KCCQ clinical summary, change—Trial running · NCT0630765221.3 vs 24.3vs Eplerenone2.5-5 mg OD · wk 12.86 · n 161NCT01807221
9 other results
  • 24.5 vs 24.3 5-10 mg OD · wk 12.86 · n 156 · Phase 2 · secondary NCT01807221
  • 29.3 vs 24.3 7.5-15 mg OD · wk 12.86 · n 158 · Phase 2 · secondary NCT01807221
  • 28.3 vs 24.3 10-20 mg OD · wk 12.86 · n 160 · Phase 2 · secondary NCT01807221
  • 22.2 vs 24.3 15-20 mg OD · wk 12.86 · n 157 · Phase 2 · secondary NCT01807221
  • 18.2 vs 20.5 2.5-5 mg OD · wk 4.29 · n 161 · Phase 2 · secondary NCT01807221
  • 19.3 vs 20.5 5-10 mg OD · wk 4.29 · n 156 · Phase 2 · secondary NCT01807221
  • 23 vs 20.5 7.5-15 mg OD · wk 4.29 · n 158 · Phase 2 · secondary NCT01807221
  • 24.9 vs 20.5 10-20 mg OD · wk 4.29 · n 160 · Phase 2 · secondary NCT01807221
  • 20.6 vs 20.5 15-20 mg OD · wk 4.29 · n 157 · Phase 2 · secondary NCT01807221

CV death or HF hospitalisation

Balcinrenone
—Trial running · NCT06307652
Finerenone
—Trial running · NCT07270367

HF hospitalisation

Balcinrenone
—Trial running · NCT06307652
Finerenone
—Trial running · NCT07270367

CV death

Balcinrenone
—Trial running · NCT06307652
Finerenone
—Trial running · NCT07270367

KCCQ clinical summary, change

Balcinrenone
—Trial running · NCT06307652
Finerenone
21.3 vs 24.3vs Eplerenone2.5-5 mg OD · wk 12.86 · n 161NCT01807221
9 other results
  • 24.5 vs 24.3 5-10 mg OD · wk 12.86 · n 156 · Phase 2 · secondary NCT01807221
  • 29.3 vs 24.3 7.5-15 mg OD · wk 12.86 · n 158 · Phase 2 · secondary NCT01807221
  • 28.3 vs 24.3 10-20 mg OD · wk 12.86 · n 160 · Phase 2 · secondary NCT01807221
  • 22.2 vs 24.3 15-20 mg OD · wk 12.86 · n 157 · Phase 2 · secondary NCT01807221
  • 18.2 vs 20.5 2.5-5 mg OD · wk 4.29 · n 161 · Phase 2 · secondary NCT01807221
  • 19.3 vs 20.5 5-10 mg OD · wk 4.29 · n 156 · Phase 2 · secondary NCT01807221
  • 23 vs 20.5 7.5-15 mg OD · wk 4.29 · n 158 · Phase 2 · secondary NCT01807221
  • 24.9 vs 20.5 10-20 mg OD · wk 4.29 · n 160 · Phase 2 · secondary NCT01807221
  • 20.6 vs 20.5 15-20 mg OD · wk 4.29 · n 157 · Phase 2 · secondary NCT01807221
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Balcinrenone: 4 of 4 rows · Finerenone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBalcinrenoneFinerenone
Dropout rate
14.3%150 mga
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
25%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0.5%b
NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3
show 6 more results
21.2%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.8%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
30.1%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
26.1%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
27.2%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
14.3%150 mga
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
—b
NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3
show 6 more results
10.6%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
12.7%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
12.7%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
15.8%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
14.8%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Serious AEs
0%150 mga
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
38.7%b
NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3
show 6 more results
27.2%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
35%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
28.8%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
31.1%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
41.9%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
150 mga
chronic kidney disease 16.7% (placebo 0%)
gingival recession 16.7% (placebo 0%)
headache 16.7% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
b
covid-19 9.8% (placebo 9.9%)
hyperkalaemia 8.4% (placebo 3.6%)
hypotension 7% (placebo 4.3%)
NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3
show 5 more results
10-20 mg OD
hypokalaemia 8.3%
renal impairment 4.7%
cardiac failure 4.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
15-20 mg OD
hypokalaemia 10.4%
cardiac failure 6.1%
dyspnoea 6.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
5-10 mg OD
hypokalaemia 12.9%
hypotension 6.7%
cardiac failure 6.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
7.5-15 mg OD
hypokalaemia 9%
hypotension 6.6%
diarrhoea 6%
NCT01807221 · Phase 2 · registry result, not featured evidence
2.5-5 mg OD
hypokalaemia 11.6%
cardiac failure 8.1%
dyspnoea 7%
NCT01807221 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Balcinrenone

UACR -58.047% (n=25) vs 230.32% (n=3) placebo @ 12wk150 mg + 10 mg
percent change · % of baseline
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
-45.01% (n=5) vs 230.32% (n=3) placebo @ 12wk150 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
-58.047% (n=25) vs 230.32% (n=7) placebo @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-45.01% (n=5) vs 230.32% (n=7) placebo @ 12wk150 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
-42.085% (n=23) vs 230.32% (n=3) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-42.085% (n=23) vs 230.32% (n=7) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-56.391% (n=32) vs 230.32% (n=3) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-56.391% (n=32) vs 230.32% (n=7) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
eGFR -5.307 vs 6.88 placebo mL @ 12wk150 mg + 10 mg
absolute change · mL
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-0.923 vs 6.88 placebo mL @ 12wk150 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
-1.16 vs 6.88 placebo mL @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.432 vs 6.88 placebo mL @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination

Finerenone

KCCQ-TSS 7.99 vs 6.43 placebo score
absolute change · score
NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3
NYHA Class Improvement 0.179 vs 0.178 placebo ratio @ 52wk
absolute value · ratio
NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3
Renal Composite 2.5% (n=3003) vs 1.8% (n=2998) placebo
event rate · % of participants
NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3 · converted to % from 75 Participants as posted
NT-proBNP 30% Reduction 30.9% (n=162) vs 37.2% (n=207) Eplerenone @ 12.857wk2.5-5 mg OD
responder rate · % of participants
NCT01807221 · Phase 2 · registry result, not featured evidence
show 4 more results
32.5% (n=157) vs 37.2% (n=207) Eplerenone @ 12.857wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
37.3% (n=158) vs 37.2% (n=207) Eplerenone @ 12.857wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
38.8% (n=160) vs 37.2% (n=207) Eplerenone @ 12.857wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
34.2% (n=158) vs 37.2% (n=207) Eplerenone @ 12.857wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
CV Hospitalization 14.2% (n=162) vs 13.5% (n=207) Eplerenone @ 4.29wk2.5-5 mg OD
event count · % of participants
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
show 14 more results
8.9% (n=157) vs 13.5% (n=207) Eplerenone @ 4.29wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
5.1% (n=158) vs 13.5% (n=207) Eplerenone @ 4.29wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
4.4% (n=160) vs 13.5% (n=207) Eplerenone @ 4.29wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
9.5% (n=158) vs 13.5% (n=207) Eplerenone @ 4.29wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
20.4% (n=162) vs 20.8% (n=207) Eplerenone @ 8.57wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
14.6% (n=157) vs 20.8% (n=207) Eplerenone @ 8.57wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
13.3% (n=158) vs 20.8% (n=207) Eplerenone @ 8.57wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
9.4% (n=160) vs 20.8% (n=207) Eplerenone @ 8.57wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
14.6% (n=158) vs 20.8% (n=207) Eplerenone @ 8.57wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
21.6% (n=162) vs 21.7% (n=207) Eplerenone @ 12.86wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 35 Participants as posted
16.6% (n=157) vs 21.7% (n=207) Eplerenone @ 12.86wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 26 Participants as posted
18.4% (n=158) vs 21.7% (n=207) Eplerenone @ 12.86wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 29 Participants as posted
13.8% (n=160) vs 21.7% (n=207) Eplerenone @ 12.86wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
17.7% (n=158) vs 21.7% (n=207) Eplerenone @ 12.86wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
CV Hospitalization 26.5% (n=162) vs 27.1% (n=207) Eplerenone2.5-5 mg OD
event count · % of participants
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 43 Participants as posted
show 4 more results
24.2% (n=157) vs 27.1% (n=207) Eplerenone*5-10 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
22.8% (n=158) vs 27.1% (n=207) Eplerenone*7.5-15 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 36 Participants as posted
16.9% (n=160) vs 27.1% (n=207) Eplerenone*10-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
21.5% (n=158) vs 27.1% (n=207) Eplerenone*15-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
HF Hospitalization or Urgent Visit 11.7% (n=162) vs 10.1% (n=207) Eplerenone @ 4.29wk2.5-5 mg OD
event count · % of participants
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
show 14 more results
7.6% (n=157) vs 10.1% (n=207) Eplerenone @ 4.29wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 12 Participants as posted
5.7% (n=158) vs 10.1% (n=207) Eplerenone @ 4.29wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
4.4% (n=160) vs 10.1% (n=207) Eplerenone @ 4.29wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
9.5% (n=158) vs 10.1% (n=207) Eplerenone @ 4.29wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
18.5% (n=162) vs 16.9% (n=207) Eplerenone @ 8.57wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted
12.7% (n=157) vs 16.9% (n=207) Eplerenone @ 8.57wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 20 Participants as posted
10.8% (n=158) vs 16.9% (n=207) Eplerenone @ 8.57wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
8.8% (n=160) vs 16.9% (n=207) Eplerenone @ 8.57wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
13.9% (n=158) vs 16.9% (n=207) Eplerenone @ 8.57wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
19.8% (n=162) vs 17.9% (n=207) Eplerenone @ 12.86wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
14% (n=157) vs 17.9% (n=207) Eplerenone @ 12.86wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
15.2% (n=158) vs 17.9% (n=207) Eplerenone @ 12.86wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 24 Participants as posted
11.3% (n=160) vs 17.9% (n=207) Eplerenone @ 12.86wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
17.7% (n=158) vs 17.9% (n=207) Eplerenone @ 12.86wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
HF Hospitalization or Urgent Visit 24.7% (n=162) vs 22.7% (n=207) Eplerenone2.5-5 mg OD
event count · % of participants
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 40 Participants as posted
show 4 more results
19.1% (n=157) vs 22.7% (n=207) Eplerenone*5-10 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted
19% (n=158) vs 22.7% (n=207) Eplerenone*7.5-15 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted
16.3% (n=160) vs 22.7% (n=207) Eplerenone*10-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 26 Participants as posted
21.5% (n=158) vs 22.7% (n=207) Eplerenone*15-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
KCCQ Clinical Summary 18.2 vs 20.5 Eplerenone score @ 4.29wk2.5-5 mg OD
absolute change · score
NCT01807221 · Phase 2 · registry result, not featured evidence
show 9 more results
19.3 vs 20.5 Eplerenone score @ 4.29wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
23 vs 20.5 Eplerenone score @ 4.29wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.9 vs 20.5 Eplerenone score @ 4.29wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
20.6 vs 20.5 Eplerenone score @ 4.29wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
21.3 vs 24.3 Eplerenone score @ 12.86wk2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.5 vs 24.3 Eplerenone score @ 12.86wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
29.3 vs 24.3 Eplerenone score @ 12.86wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
28.3 vs 24.3 Eplerenone score @ 12.86wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
22.2 vs 24.3 Eplerenone score @ 12.86wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
EQ-5D Index 0.02 vs 0.06 Eplerenone score @ 4.29wk2.5-5 mg OD
absolute change · score
NCT01807221 · Phase 2 · registry result, not featured evidence
show 9 more results
0.02 vs 0.06 Eplerenone score @ 4.29wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.07 vs 0.06 Eplerenone score @ 4.29wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.06 vs 0.06 Eplerenone score @ 4.29wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.02 vs 0.06 Eplerenone score @ 4.29wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.03 vs 0.08 Eplerenone score @ 12.86wk2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.04 vs 0.08 Eplerenone score @ 12.86wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.08 vs 0.08 Eplerenone score @ 12.86wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.1 vs 0.08 Eplerenone score @ 12.86wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.06 vs 0.08 Eplerenone score @ 12.86wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
EQ-5D Index 0.01 vs 0.06 Eplerenone score2.5-5 mg OD
absolute change · score
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
show 4 more results
0.01 vs 0.06 Eplerenone score5-10 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.08 vs 0.06 Eplerenone score7.5-15 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.07 vs 0.06 Eplerenone score10-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.04 vs 0.06 Eplerenone score15-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence

Chronic Kidney Disease

Shared mechanism: Mineralocorticoid receptor · full Chronic Kidney Disease pipeline

Balcinrenone

Developed by AstraZeneca

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04595370 · Phase 2 · completed

The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.

Next expected readout: July 2030 · NCT07624305 (registry estimate)

Reported efficacy

Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) (missed)

Result source: NCT04595370

Finerenone · Kerendia

Marketed by Bayer

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT02540993 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and large, with 5,734 participants randomized nearly equally between finerenone and placebo. Its hard clinical kidney endpoint was met: 504 participants receiving finerenone versus 600 receiving placebo experienced the primary outcome, with a statistically significant hazard ratio of 0.825 (p=0.0014).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Mean rate of change as measured by the total slope of eGFR from baseline to Month-32. (From baseline to month 32): Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001) (met)

Result source: NCT05047263

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBalcinrenoneFinerenone
Kidney composite outcome—Trial running · NCT07624305—Not posted · NCT05047263
UACR, % change-58.0% vs 230.3%−288.4 vs placebo150 mg + 10 mg · wk 12 · n 25NCT04595370
7 other results
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · secondary NCT04595370
—Not posted · NCT05047263
eGFR slope—Trial running · NCT07624305—Not posted · NCT05047263
Haemoglobin, change—Trial running · NCT07624305—Not posted · NCT05047263

Kidney composite outcome

Balcinrenone
—Trial running · NCT07624305
Finerenone
—Not posted · NCT05047263

UACR, % change

Balcinrenone
-58.0% vs 230.3%−288.4 vs placebo150 mg + 10 mg · wk 12 · n 25NCT04595370
7 other results
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · secondary NCT04595370
Finerenone
—Not posted · NCT05047263

eGFR slope

Balcinrenone
—Trial running · NCT07624305
Finerenone
—Not posted · NCT05047263

Haemoglobin, change

Balcinrenone
—Trial running · NCT07624305
Finerenone
—Not posted · NCT05047263
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Balcinrenone: 4 of 4 rows · Finerenone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBalcinrenoneFinerenone
Dropout rate
14.3%150 mga
NCT04595370 · Phase 2
show 3 more results
25%150 mg + 10 mg
NCT04595370 · Phase 2 · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · combination
1.5%b
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 10 more results
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone Group
NCT05254002 · Phase 2 · registry result, not featured evidence
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
1%
NCT05013008 · Phase 2 · registry result, not featured evidence
21.2%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.8%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
30.1%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
26.1%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
27.2%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
14.3%150 mga
NCT04595370 · Phase 2
show 3 more results
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · combination
—b
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 10 more results
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone Group
NCT05254002 · Phase 2 · registry result, not featured evidence
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—
NCT05013008 · Phase 2 · registry result, not featured evidence
10.6%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
12.7%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
12.7%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
15.8%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
14.8%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Serious AEs
0%150 mga
NCT04595370 · Phase 2
show 3 more results
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · combination
31.9%b
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 10 more results
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
6.1%Finerenone Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—
NCT05013008 · Phase 2 · registry result, not featured evidence
27.2%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
35%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
28.8%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
31.1%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
41.9%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
150 mga
chronic kidney disease 16.7% (placebo 0%)
gingival recession 16.7% (placebo 0%)
headache 16.7% (placebo 0%)
NCT04595370 · Phase 2
show 3 more results
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · combination
b
hyperkalaemia 14.9% (placebo 7.5%)
nasopharyngitis 8.5% (placebo 8.8%)
anaemia 7.1% (placebo 6.3%)
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 7 more results
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
hyperkalaemia 10.2%
glomerular filtration rate decreased 4.2%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence
10-20 mg OD
hypokalaemia 8.3%
renal impairment 4.7%
cardiac failure 4.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
15-20 mg OD
hypokalaemia 10.4%
cardiac failure 6.1%
dyspnoea 6.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
5-10 mg OD
hypokalaemia 12.9%
hypotension 6.7%
cardiac failure 6.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
7.5-15 mg OD
hypokalaemia 9%
hypotension 6.6%
diarrhoea 6%
NCT01807221 · Phase 2 · registry result, not featured evidence
2.5-5 mg OD
hypokalaemia 11.6%
cardiac failure 8.1%
dyspnoea 7%
NCT01807221 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 10 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Balcinrenone

UACR -58.047% (n=25) vs 230.32% (n=3) placebo @ 12wk150 mg + 10 mg
percent change · % of baseline
NCT04595370 · Phase 2 · combination
show 7 more results
-45.01% (n=5) vs 230.32% (n=3) placebo @ 12wk150 mg
NCT04595370 · Phase 2
-58.047% (n=25) vs 230.32% (n=7) placebo @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · combination
-45.01% (n=5) vs 230.32% (n=7) placebo @ 12wk150 mg
NCT04595370 · Phase 2
-42.085% (n=23) vs 230.32% (n=3) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · combination
-42.085% (n=23) vs 230.32% (n=7) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · combination
-56.391% (n=32) vs 230.32% (n=3) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · combination
-56.391% (n=32) vs 230.32% (n=7) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · combination
eGFR -5.307 vs 6.88 placebo mL @ 12wk150 mg + 10 mg
absolute change · mL
NCT04595370 · Phase 2 · combination
show 3 more results
-0.923 vs 6.88 placebo mL @ 12wk150 mg
NCT04595370 · Phase 2
-1.16 vs 6.88 placebo mL @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · combination
-1.432 vs 6.88 placebo mL @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · combination

Finerenone

Renal Composite Endpoint 40 17.8% (n=2833) vs 21.1% (n=2841) placebo
event count · % of participants
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to % from 504 Participants as posted
MACE HHF Composite 13% (n=2833) vs 14.8% (n=2841) placebo
event count · % of participants
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to % from 367 Participants as posted
UACR 0.655 vs 0.952 placebo ratio @ 16wk
ratio to baseline · ratio
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 3 more results
0.483 vs 0.708 Empagliflozin ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.483 vs 0.683 Finerenone ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.818 vs 0.853 Finerenone ratio @ 30wk
NCT05254002 · Phase 2 · registry result, not featured evidence
Renal Composite Endpoint 57 8.9% (n=2833) vs 11.5% (n=2841) placebo
event count · % of participants
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to % from 252 Participants as posted
eGFR 30% Decline 6.3% (n=268) vs 3.8% (n=264) Finerenone @ 4.3wk
event count · % of participants
NCT05254002 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
NT-proBNP 30% Reduction 30.9% (n=162) vs 37.2% (n=207) Eplerenone @ 12.857wk2.5-5 mg OD
responder rate · % of participants
NCT01807221 · Phase 2 · registry result, not featured evidence
show 4 more results
32.5% (n=157) vs 37.2% (n=207) Eplerenone @ 12.857wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
37.3% (n=158) vs 37.2% (n=207) Eplerenone @ 12.857wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
38.8% (n=160) vs 37.2% (n=207) Eplerenone @ 12.857wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
34.2% (n=158) vs 37.2% (n=207) Eplerenone @ 12.857wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
CV Hospitalization 14.2% (n=162) vs 13.5% (n=207) Eplerenone @ 4.29wk2.5-5 mg OD
event count · % of participants
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
show 14 more results
8.9% (n=157) vs 13.5% (n=207) Eplerenone @ 4.29wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
5.1% (n=158) vs 13.5% (n=207) Eplerenone @ 4.29wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
4.4% (n=160) vs 13.5% (n=207) Eplerenone @ 4.29wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
9.5% (n=158) vs 13.5% (n=207) Eplerenone @ 4.29wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
20.4% (n=162) vs 20.8% (n=207) Eplerenone @ 8.57wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
14.6% (n=157) vs 20.8% (n=207) Eplerenone @ 8.57wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
13.3% (n=158) vs 20.8% (n=207) Eplerenone @ 8.57wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
9.4% (n=160) vs 20.8% (n=207) Eplerenone @ 8.57wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
14.6% (n=158) vs 20.8% (n=207) Eplerenone @ 8.57wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
21.6% (n=162) vs 21.7% (n=207) Eplerenone @ 12.86wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 35 Participants as posted
16.6% (n=157) vs 21.7% (n=207) Eplerenone @ 12.86wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 26 Participants as posted
18.4% (n=158) vs 21.7% (n=207) Eplerenone @ 12.86wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 29 Participants as posted
13.8% (n=160) vs 21.7% (n=207) Eplerenone @ 12.86wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
17.7% (n=158) vs 21.7% (n=207) Eplerenone @ 12.86wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
CV Hospitalization 26.5% (n=162) vs 27.1% (n=207) Eplerenone2.5-5 mg OD
event count · % of participants
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 43 Participants as posted
show 4 more results
24.2% (n=157) vs 27.1% (n=207) Eplerenone*5-10 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
22.8% (n=158) vs 27.1% (n=207) Eplerenone*7.5-15 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 36 Participants as posted
16.9% (n=160) vs 27.1% (n=207) Eplerenone*10-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
21.5% (n=158) vs 27.1% (n=207) Eplerenone*15-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
KCCQ Clinical Summary 18.2 vs 20.5 Eplerenone score @ 4.29wk2.5-5 mg OD
absolute change · score
NCT01807221 · Phase 2 · registry result, not featured evidence
show 9 more results
19.3 vs 20.5 Eplerenone score @ 4.29wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
23 vs 20.5 Eplerenone score @ 4.29wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.9 vs 20.5 Eplerenone score @ 4.29wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
20.6 vs 20.5 Eplerenone score @ 4.29wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
21.3 vs 24.3 Eplerenone score @ 12.86wk2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.5 vs 24.3 Eplerenone score @ 12.86wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
29.3 vs 24.3 Eplerenone score @ 12.86wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
28.3 vs 24.3 Eplerenone score @ 12.86wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
22.2 vs 24.3 Eplerenone score @ 12.86wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
EQ-5D Index 0.02 vs 0.06 Eplerenone score @ 4.29wk2.5-5 mg OD
absolute change · score
NCT01807221 · Phase 2 · registry result, not featured evidence
show 9 more results
0.02 vs 0.06 Eplerenone score @ 4.29wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.07 vs 0.06 Eplerenone score @ 4.29wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.06 vs 0.06 Eplerenone score @ 4.29wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.02 vs 0.06 Eplerenone score @ 4.29wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.03 vs 0.08 Eplerenone score @ 12.86wk2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.04 vs 0.08 Eplerenone score @ 12.86wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.08 vs 0.08 Eplerenone score @ 12.86wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.1 vs 0.08 Eplerenone score @ 12.86wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.06 vs 0.08 Eplerenone score @ 12.86wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
EQ-5D Index 0.01 vs 0.06 Eplerenone score2.5-5 mg OD
absolute change · score
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
show 4 more results
0.01 vs 0.06 Eplerenone score5-10 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.08 vs 0.06 Eplerenone score7.5-15 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.07 vs 0.06 Eplerenone score10-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.04 vs 0.06 Eplerenone score15-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Balcinrenone's landscape · Finerenone's landscape